Evidence map›Paper›PMID 31544888›Full record

ArticleAntibodies (Basel, Switzerland)2018

Rapid Generation of Monoclonal Antibodies from Single B Cells by Ecobody Technology.

Teruyo Ojima-Kato, Shiomi Morishita, Yoshino Uchida, Satomi Nagai, Takaaki Kojima, Hideo Nakano

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Evolution ofInternational journal of molecular sciences · 2020
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Teruyo Ojima-KatoiBody Inc., Furo-cho 1, Chikusa-ku, Nagoya 464-0814, Japan. kato.teruyo@ibody.co.jp.ORCID 0000-0001-5290-5176
Shiomi MorishitaGraduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan. morishita.shiomi@molbiotech-nagoya.org.
Yoshino UchidaGraduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan. uchida.yoshino@molbiotech-nagoya.org.
Satomi NagaiiBody Inc., Furo-cho 1, Chikusa-ku, Nagoya 464-0814, Japan. nagai.satomi@molbiotech-nagoya.org.
Takaaki KojimaGraduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan. kojimat@nuagr1.agr.nagoya-u.ac.jp.
Hideo NakanoiBody Inc., Furo-cho 1, Chikusa-ku, Nagoya 464-0814, Japan. hnakano@agr.nagoya-u.ac.jp.
Nagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single B cell sampling following to direct gene amplification and transient expression in animal cells has been recognized as powerful monoclonal antibodies (mAbs) screening strategies. Here we report Ecobody technology which allows mAbs screening from single B cells in two days This technology uses

Indexed as

human antibodiesrabbit antibodiessingle B cell technology

Identifiers

PMID31544888
PMCPMC6698955
OpenAlexW2900377091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.